A review of the LARIAT device: insights from the cumulative clinical experience

SpringerPlus

Table 5 LARIAT LAAO success and durability and procedural and late adverse events from published series with greater than 10 patients and closed-chest ligation¹ (Price and Gibson 2014; Stone et al. 2013; Bartus et al. 2013; Massumi et al. 2013; Miller et al. 2014)

	Number of patients
Device success^a	313/334 (94 %)
Device durability^b	222/226 (98 %)
Procedural adverse events^c	64/334 (14.7 %)
Death	1/334 (0.3 %)
LAA laceration	6/334 (1.8 %)
CVA/TIA	1/334 (0.3 %)
Significant pericardial effusion^d	25/334 (7.5 %)
Complication with surgical intervention	8/334 (2.4 %)
Pericarditis^e	15/180 (8.3 %)
Pleural effusion	8/334 (2.4)
Late adverse events	33/334 (9.9 %)
Death	6/334 (1.8 %)
CVA/TIA	6/334 (1.8 %)
Pleural effusion	6/334 (1.8 %)
Pericardial effusion	10/334 (3.0 %)
Thrombus in LA or LAA by TEE/CT	5/227 (2.2 %)

^aSuccessful deployment of device with <5 mm leak by TEE/CT
^bLAA leak <5 mm by last follow-up TEE/CT in those whom follow-up imaging available
^cEvents occurring prior to discharge and not including pericarditis
^dEffusions requiring pericardiocentesis or vasopressor therapy
^ePrice et al. did not provide pericarditis rate